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Abstract
Background: Studies show the In-hospital Mortality for Pulmonary embolism using Claims daTa (IMPACT) rule can
accurately identify pulmonary embolism (PE) patients at low-risk of early mortality in a retrospective setting using
only claims for the index admission. We sought to externally validate IMPACT, Pulmonary Embolism Severity Index
(PESI), simplified PESI (sPESI) and Hestia for predicting early mortality.
Methods: We identified consecutive adults admitted for objectively-confirmed PE between 10/21/2010 and 5/12/
2015. Patients undergoing thrombolysis/embolectomy within 48 h were excluded. All-cause in-hospital and 30 day
mortality (using available Social Security Death Index data through January 2014) were assessed and prognostic
accuracies of IMPACT, PESI, sPESI and Hestia were determined.
Results: Twenty-one (2.6 %) of the 807 PE patients died before discharge. All rules classified 26.1–38.3 % of patients
as low-risk for early mortality. Fatality among low-risk patients was 0 % (sPESI and Hestia), 0.4 % (IMPACT) and 0.6 %
(PESI). IMPACT’s sensitivity was 95.2 % (95 % confidence interval [CI] = 74.1–99.8 %), and the sensitivities of clinical
rules ranged from 91 (PESI)-100 % (sPESI and Hestia). Specificities of all rules ranged between 26.8 and 39.1 %. Of
573 consecutive patients in the 30 day mortality analysis, 33 (5.8 %) died. All rules classified 27.9–38.0 % of patients
as low-risk, and fatality occurred in 0 (Hestia)-1.4 % (PESI) of low-risk patients. IMPACT’s sensitivity was 97.0 %
(95%CI = 82.5–99.8 %), while sensitivities for clinical rules ranged from 91 (PESI)-100 % (Hestia). Specificities of rules
ranged between 29.6 and 39.8 %.
Conclusion: In this analysis, IMPACT identified low-risk PE patients with similar accuracy as clinical rules. While not
intended for prospective clinical decision-making, IMPACT appears useful for identification of low-risk PE patient in
retrospective claims-based studies.
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Background
Guidelines suggest that patients with pulmonary embol-
ism (PE) who are identified to have a low-risk of early
post-PE all-cause mortality may be candidates for abbre-
viated hospital admission or outpatient treatment if ap-
propriate follow-up can be arranged [1, 2]. Data from
randomized trials and observational studies suggest that
early discharge or outpatient treatment of low-risk PE
patients is feasible and safe [3, 4].
A prior meta-analysis suggested at least one-third of
acute PE patients could be classified as low-risk for early
mortality according to clinical prediction rules [5]. This
same meta-analysis identified the Pulmonary Embolism
Severity Index (PESI), simplified PESI (sPESI) and Hestia
clinical prediction rules as having high sensitivities and
negative predictive values (NPVs) for identifying low-risk
PE patients. In order to use PESI [6], sPESI [7] and
Hestia [8] in the risk stratification of a patient with PE,
access to vital signs, laboratory values, comorbid condi-
tions and a cognitive evaluation at presentation is neces-
sary. While PESI, sPESI and Hestia can be helpful in
clinical practice, the extensive clinical data required to
score these rules are not commonly found in claims
databases or easily accessible to individual hospitals/
health-systems. As a result, the utility of PESI, sPESI or
Hestia for retrospective identification of low-risk pa-
tients with PE is limited.
While not originally derived to aid in prognostication
in a prospective clinical setting, the In-hospital Mortality
for Pulmonary embolism using Claims daTa (IMPACT)
multivariable prediction rule utilizes data accessible
within claims databases and/or claims from individual
hospitals to retrospectively risk stratify patients with PE
for early mortality [9]. Prior validation studies suggest
IMPACT can accurately identify pulmonary embolism
(PE) patients at low-risk of early mortality [10, 11].
The ability of IMPACT to correctly identify patients at
low- and higher-risk of early mortality has not previ-
ously been compared to analogous clinical prediction
rules. Therefore, using data from a single center, this
study sought to externally validate IMPACT, PESI,
sPESI and Hestia for predicting in-hospital and 30 day
post-PE mortality.
Methods
Preparation of this study report was in accordance with
the Transparent reporting of a multivariable prediction
model for individual prognosis or diagnosis (TRIPOD)
statement [12]. For this retrospective cohort study, we
identified consecutive patients diagnosed with acute PE
between October 21, 2010 and May 12, 2015 using
computerized claims records for admissions to Hartford
Hospital (Hartford, Connecticut, USA). The hospital’s
computerized claims system contains information on
source of admission, International Classification of Dis-
eases, Ninth Revision, Clinical Modification (ICD-9-CM)
diagnosis and procedure codes, admission and discharge
dates and discharge status. To be eligible for inclusion
into this study, patients ≥18 years of age presenting to
our institution had to have a primary diagnosis of PE
(ICD-9-CM code = 415.1x). Consistent with prior stud-
ies, we excluded patients lacking objective confirmation
of acute PE according to clinical guidelines. The follow-
ing were considered confirmatory studies for the diagno-
sis of acute PE: high probability perfusion-ventilation
lung scan (V/Q scan), computed tomography pulmonary
angiography (CTPA) or pulmonary angiography diagnos-
tic for PE, or a non-diagnostic V/Q scan or CTPA in
combination with an abnormal compression ultrasonog-
raphy of the lower extremities. Consistent with many
prior studies of PE clinical prediction rules [5], subjects
that received thrombolysis and/or pulmonary embolec-
tomy within the 48 h of presentation were excluded as
clinical guidelines do not consider such patients low-risk
[1, 2]. All patients included in this study were managed
according to usual clinical practice for our institution.
Risk stratification of patients with acute PE using
IMPACT, PESI, sPESI and Hestia was performed according
to published methods (Additional file 1) [6–9]. Patients
with an IMPACT predicted mortality risk ≤1.5 % [9], PESI
score ≤85 [6] or a sPESI or Hestia scores =0 [7, 8] were
classified as low-risk for early mortality. Estimated mortality
risk according to the claims-based IMPACT predic-
tion rule [estimated % absolute risk = 1/(1 + exp(-x);
where x = −5.833 + (0.026*age) + (0.402*myocardial infarc-
tion) + (0.368*chronic lung disease) + (0.464*stroke) + (0.6
38*prior major bleeding) + (0.298*atrial fibrillation) + (1.06
1*cognitive impairment) + (0.554*heart failure) + (0.364*
renal failure) + (0.484*liver disease) + (0.523*coagulopa-
thy) + (1.068*cancer)] was determined using all available
hospital claims data (i.e., ICD-9-CM diagnosis and pro-
cedural codes) for each patient’s index PE encounter along
with their age at time of presentation. ICD-9-CM coding
for relevant IMPACT co-morbidities were performed ac-
cording to the original IMPACT derivation paper [9]. Data
necessary to classify patients as low- or high-risk of early
mortality according to the PESI, sPESI and Hestia clinical
prediction rules [6–8] were obtained by linking all in-
cluded patients identified through hospital claims to the
hospital’s electronic health record (EHR). We used vital
signs (heart rate, blood pressure, respiratory rate, oxygen
[O2] saturation, body temperature), laboratory values
(serum creatinine, platelet count, total bilirubin) and men-
tal status assessments obtained as close to the time of
presentation for the index PE encounter as possible to
score each of the clinical prediction rules [6]. For all pa-
tients admitted through the emergency department, the
first vital sign, laboratory value and/or mental status
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assessment upon presentation (but within 24 h) was uti-
lized. For patients directly admitted to the hospital we
used the first values recorded on the day of hospital ad-
mission. Consistent with previous studies of this type, miss-
ing vital, laboratory and mental status assessment data were
assumed to be normal [6]. For PESI, sPESI and Hestia, the
presence of cancer, heart failure, chronic lung disease,
severe liver disease (defined as a total bilirubin
≥2.5 mg/dL), heparin-induced thrombocytopenia and
recent clinical events (gastrointestinal bleeding within
14 days, stroke with 4 weeks, surgery with 2 weeks)
were assessed at time of hospital admission for the
index PE encounter. All required data was abstracted
from the electronic health record (including vital signs,
laboratory values and emergency department, admis-
sion and consult notes) by trained study personnel
blinded to study outcome.
All-cause in-hospital and 30 day post-PE mortality
served as a priori endpoints for this study. In-hospital
mortality was determined using the discharge status
field for the index admission within the hospital bill-
ing system and electronic health record. Thirty-day
mortality was based upon searches of the Social Se-
curity Death Index (SSDI) [11] performed >6 months
after the last day of eligible inclusion in this analysis.
Computerized health-system encounter data from our
hospital’s billing records were queried for subsequent
emergency visit claims, clinic visits and/or hospital
readmissions outside of 30 days. These were used as
confirmatory markers of vital status at 30 days. Begin-
ning in March 2014, rules regarding access to data
within the SSDI changed; restricting the release of
three most recent years of data [13, 14]. For this rea-
son, our 30 day mortality endpoint was assessed only
in the subset of consecutive patients presenting to the
hospital prior to January 31, 2014.
Baseline characteristics are described with means ±
SDs for continuous data and counts and proportions
for categorical data. Sensitivity, specificity and negative
and positive predictive values for predicting early mor-
tality were calculated for IMPACT, PESI, sPESI and
Hestia along with 95 % confidence intervals (CIs). C-
statistics were computed to evaluate each rule’s overall
discriminative power. All database management and
statistical analyses were performed using IBM SPSS
Statistics version 22.0 (IBM Corp., Armonk, NY, USA).
The study was approved by the Hartford Hospital insti-
tutional review board.
Results
A total of 861 patients with a primary ICD-9-CM code
for acute PE and objective confirmation of diagnosis
were identified (Fig. 1). Of these, 54 received thrombo-
lytic therapy/embolectomy within 48 h of presentation,
leaving 807 for analysis. Baseline characteristics of the
cohort, stratified by low- and high-risk for each rule are
shown in Table 1. Two-hundred and thirty-four patients
presented with PE after January 2014 and were excluded
from the 30 day mortality endpoint analysis, as SSDI
data are not available for patients past this time point.
The baseline characteristics of the 30 day mortality ana-
lysis patient subset were similar to the overall population
(Additional file 1: Table S1).
The IMPACT, PESI, sPESI and Hestia scores (mean ±
SD) for the complete cohort of 807 PE patients were
3.9 ± 4.3, 96.4 ± 33.3, 1.1 ± 0.9 and 1.3 ± 1.1, respectively.
While mean age for patients was 64.1 ± 16.57; when di-
chotomized into risk groups, high-risk patients were
considerably older, regardless of prediction rule used.
At time of presentation, mean vital sign values were
within normal ranges in the overall analysis population;
but more than half of the subjects required O2 supple-
mentation to maintain saturations >90 %. The use of
thrombolysis and/or embolectomy after 48 h was infre-
quent, occurring in only 4 (0.5 %) of patients.
The overall incidence of all-cause in-hospital mortality
was 2.6 % (21/807). IMPACT, PESI, sPESI and Hestia
classified 26 % (Hestia)-38 % (PESI) of the cohort as
low-risk for early post-PE mortality. Fatality among low-
risk patients was low (0–0.6 %), corresponding to NPVs
of 99.4 (PESI)-100 % (sPESI and Hestia) (Table 2).
IMPACT’s sensitivity was 95.2 % (95 % CI = 74.1–
99.8 %), and the sensitivities of clinical rules ranged from
91 (PESI)-100 % (sPESI and Hestia). Specificities of all
rules ranged between 26.8 (Hestia)-39.1 % (PESI) and C-
statistics from 0.76 (sPESI)-0.86 (Hestia). Additional file
1: Table S2 describes the characteristics of patients who
died in-hospital and had discordant risk categorization
across any of the four prediction rules.
Among the subset of 573 patients accessible within the
SSDI, 33 (5.8 %) died of any cause within 30 days of
presentation for PE. All rules classified 27.9 (Hestia)-
38.0 % (PESI) of PE patients as low-risk, and fatality oc-
curred in 0.0 % (Hestia)-1.4 % (PESI) of low-risk patients
(NPVs = 98.6–100 %) (Table 3). IMPACT’s sensitivity for
predicting 30 day mortality was 97.0 % (95%CI = 82.5–
99.8 %), while sensitivities for clinical rules ranged from
91 (PESI)-100 % (Hestia). Specificities of rules ranged
between 29.6 % (Hestia)-39.8 % (PESI) and their C statis-
tics ranged from 0.73 (sPESI)-0.81 (PESI). Additional file
1: Table S3 describes the characteristics of patients who
died within 30 days of presentation and had discordant
risk categorization across any of the 4 prediction rules.
Discussion
In this analysis, the claims-based IMPACT prediction rule
displayed prognostic accuracy similar to that of commonly
used clinical risk stratification rules, including PESI and
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sPESI (which have been prospectively validated for identi-
fication of low-risk PE patients) and the Hestia criteria
(which was prospectively designed to identify patients
whom could be treated as outpatients). The 4 rules evalu-
ated in this study classified between 1/4th and 2/5ths of
patients as low-risk. Each exhibited sensitivities >90 %,
NPVs >98.6 % and specificities <40 % for predicting in-
hospital or 30 day all-cause mortality, and these findings
are consistent with prior derivation and validation studies.
To our knowledge, this is the first external validation
study of Hestia [5, 9–11]. Taken together, our results sug-
gests each of the four rules can identify a cohort of low-
risk PE patients whom are unlikely to die within the first
30 days of presentation. However, because a minority of
patients with PE (<6 % in our study) die within 30 days,
these prognostic rules classify a substantial number of pa-
tients who ultimately survive into higher-risk groups
(hence their lower specificities). Prognostic tests seldom
have both high sensitivity and specificity. Therefore, when
using a prognostic test to decide upon implementing a less
conservative treatment strategy (e.g., discharging a patient
with acute PE directly from the emergency department)
higher sensitivity and NPV values are preferable.
The American College of Chest Physicians and the
European Society of Cardiology guidelines support early
discharge and/or home treatment of PE patients at low-
risk for early mortality as long as they have adequate
home circumstances [1, 2]. These guidelines suggest that
clinicians use validated clinical prediction rules to assist
in identification and selection of low-risk patients. Al-
though in this analysis IMPACT displayed a similar abil-
ity to identify low-risk PE patients as PESI, sPESI and
Hestia; IMPACT was not originally derived or validated
to assist in prospective clinical decision-making (and is
relatively more computationally complex compared to
clinical prediction rules), and it should not be used for
individual patient decision-making [9]. However, IM-
PACT appears valid for retrospective identification of
low-risk PE patients and therefore could be used to aid
in the performance of real-world outcomes studies and
to enable payer/institution benchmarking of rates of
low-risk PE patients treated at home or following an ab-
breviated admission. Using claim s data as described by
IMPACT may have advantages over obtaining highly
granular clinical information from the EHR (including
reduced time and effort requirements).
Fig. 1 Identified PE patients and distribution of risk classes. IMPACT = hrs = hours; In-hospital Mortality for Pulmonary embolism using Claims daTa;
PE = pulmonary embolism; PESI = Pulmonary Embolism Severity Index; SSDI = social security death index; sPESI = simplified Pulmonary Embolism
Severity Index
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Table 1 Characteristics of pulmonary embolism patients
















N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%)
N = 807 N = 230 N = 577 N = 309 N = 498 N = 250 N = 557 N = 211 N = 596
Age (years, mean ± SD) 64.1 ± 16.47 46.4 ± 11.36 71.2 ± 12.38 51.9 ± 14.39 71.6 ± 12.76 56.3 ± 14.49 67.6 ± 16.12 59.9 ± 17.10 65.6 ± 16.00
> 80 years 145 (18.0) 0 (0) 145 (25.1) 9 (2.9) 136 (27.3) 0 (0) 145 (26.0) 27 (12.8) 118 (19.7)
Male gender 372 (46.1) 114 (49.6) 258 (44.7) 135 (43.7) 237 (47.6) 140 (56.0) 232 (41.7) 99 (46.9) 273 (45.8)
Cancer 254 (31.5) 18 (7.8) 236 (40.9) 15 (4.9) 239 (48.0) 0 (0) 254 (45.5) 51 (24.2) 203 (34.1)
Cancer (ICD-9-CM) 154 (19.1) 0 (0) 154 (26.7) 10 (3.2) 144 (28.9) 3 (1.2) 151 (27.1) 25 (11.8) 129 (21.6)
Chronic cardiopulmonary disease 230 (28.5) 29 (12.6) 201 (34.3) 42 (13.6) 188 (37.8) 0 (0) 230 (41.3) 37 (17.5) 193 (32.4)
Chronic lung disease 198 (24.5) 27 (11.7) 171 (29.6) 40 (12.9) 158 (31.7) 0 (0) 198 (35.5) 34 (16.1) 164 (27.5)
Chronic lung disease (ICD-9-CM) 224 (27.8) 22 (9.6) 202 (35.0) 47 (15.2) 177 (35.5) 7 (2.8) 217 (39.0) 36 (17.1) 188 (31.5)
Heart failure 62 (7.7) 2 (0.9) 60 (10.3) 3 (1.0) 59 (11.8) 0 (0) 62 (11.1) 4 (1.9) 58 (9.7)
Heart failure (ICD-9-CM) 75 (9.3) 1 (0.4) 74 (12.8) 9 (2.9) 66 (13.3) 5 (2.0) 70 (12.6) 8 (3.8) 67 (11.2)
Altered mental status at presentation 42 (5.2) 3 (1.3) 39 (6.8) 0 (0) 42 (8.4) 6 (2.4) 36 (6.5) 4 (1.9) 38 (6.4)
Cognitive impairment (ICD-9-CM) 60 (7.4) 0 (0) 60 (10.4) 7 (2.3) 53 (10.6) 6 (2.4) 54 (9.7) 7 (3.3) 53 (8.9)
Pulse (beats/min, mean ± SD) 93.2 ± 18.92 94.0 ± 18.51 92.9 ± 19.10 91.6 ± 17.35 94.1 ± 19.78 85.6 ± 13.38 96.6 ± 20.04 87.6 ± 17.73 95.2 ± 18.96
Pulse ≥ 110 beats/min 169 (20.9) 56 (24.3) 113 (19.6) 47 (15.2) 122 (24.5) 0 (0) 169 (30.3) 29 (13.7) 140 (23.5)
Systolic blood pressure (mmHg, mean ± SD) 133.6 ± 22.90 134.4 ± 21.75 133.3 ± 23.35 136.4 ± 21.32 131.9 ± 23.69 136.8 ± 21.60 132.2 ± 23.33 139.8 ± 22.30 131.4 ± 22.70
Systolic blood pressure <100 mmHg 36 (4.5) 7 (3.0) 29 (5.0) 3 (1.0) 33 (6.6) 0 (0) 36 (6.5) 3 (1.4) 33 (5.5)
O2 saturation (%, mean ± SD) 96.3 ± 3.50 96.8 ± 3.83 96.1 ± 3.34 96.3 ± 2.42 95.9 ± 3.97 97.0 ± 2.35 96.0 ± 3.87 97.1 ± 2.12 96.0 ± 3.83
O2 saturation <90 % 32 (4.0) 6 (2.6) 26 (4.5) 1 (0.3) 31 (6.2) 0 (0) 32 (5.7) 0 (0) 32 (5.4)
Oxygen needed to maintain O2 saturation >90 % for >24 h 412 (51.1) 79 (34.3) 333 (57.7) 112 (36.2) 300 (60.2) 90 (36.0) 322 (57.8) 0 (0) 412 (69.1)
Respiratory rate (breaths/min, mean ± SD) 19.1 ± 3.56 18.7 ± 3.31 19.3 ± 3.64 18.5 ± 2.20 19.5 ± 4.14 18.5 ± 2.51 19.4 ± 3.90 18.2 ± 2.37 19.5 ± 3.84
Respiratory rate ≥30 breaths/min 19 (2.4) 2 (0.8) 17 (2.9) 0 (0) 19 (3.8) 2 (0.8) 17 (3.1) 2 (0.9) 17 (2.9)
Temperature (degrees Celsius, mean ± SD) 97.6 ± 1.38 97.8 ± 1.29 97.6 ± 1.41 97.9 ± 1.38 97.4 ± 1.47 97.6 ± 1.28 97.6 ± 1.40 97.4 ± 1.24 97.7 ± 1.42
Temperature <36° Celsius 206 (25.5) 47 (20.4) 159 (27.6) 40 (12.9) 166 (33.3) 68 (27.2) 138 (24.8) 60 (28.4) 146 (24.5)
Thrombolysis or embolectomy > 48 h 4 (0.5) 2 (0.9) 2 (0.3) 3 (1.0) 1 (0.2) 3 (1.2) 1 (0.2) 0 (0) 4 (0.7)
High risk of bleedingb 101 (12.5) 37 (16.1) 64 (11.1) 48 (15.5) 53 (10.6) 37 (14.8) 64 (11.5) 0 (0) 101 (16.9)
PE on anticoagulation 62 (7.7) 17 (7.4) 45 (7.8) 21 (6.7) 41 (8.2) 11 (4.4) 51 (9.2) 0 (0) 62 (10.4)
History of heparin-induced thrombocytopenia 5 (0.6) 1 (0.4) 4 (0.7) 2 (0.6) 3 (0.6) 2 (0.8) 3 (0.5) 0 (0) 5 (0.8)
Medical or social reason for admissionc 237 (29.3) 43 (18.7) 194 (33.6) 64 (20.7) 173 (34.7) 42 (16.9) 195 (34.9) 0 (0) 237 (39.8)
Need for intravenous pain medication for > 24 h 87 (10.8) 43 (18.7) 44 (7.6) 48 (15.5) 39 (7.8) 32 (12.8) 55 (9.9) 0 (0) 87 (14.6)











Table 1 Characteristics of pulmonary embolism patients (Continued)
Liver disease (ICD-9-CM) 6 (0.7) 0 (0) 6 (1.0) 3 (1.0) 3 (0.6) 2 (0.8) 4 (0.7) 0 (0) 6 (1.0)
Creatinine clearance <30 mL/min 31 (3.8) 2 (0.9) 29 (5.0) 11 (3.6) 20 (4.0) 7 (2.8) 24 (4.3) 0 (0) 31 (5.2)
Renal failure (ICD-9-CM) 60 (7.4) 2 (0.9) 58 (10.1) 18 (5.8) 42 (8.4) 16 (6.4) 44 (7.9) 8 (3.8) 52 (8.7)
Hemodynamically unstablee 94 (11.6) 24 (10.4) 70 (12.1) 30 (9.7) 64 (12.9) 17 (6.8) 77 (13.8) 0 (0) 94 (15.8)
Myocardial infarction (ICD-9-CM) 40 (5.0) 4 (1.7) 36 (6.2) 15 (4.9) 25 (5.0) 16 (6.4) 24 (4.3) 2 (0.9) 38 (6.4)
Cerebrovascular disease (ICD-9-CM) 11 (1.4) 0 (0) 11 (1.9) 5 (1.6) 6 (1.2) 4 (1.6) 7 (1.3) 2 (0.9) 9 (1.5)
Prior major bleeding (ICD-9-CM) 28 (3.5) 1 (0.4) 27 (4.7) 8 (2.6) 20 (4.0) 5 (2.0) 23 (4.1) 3 (1.4) 25 (4.2)
Atrial fibrillation (ICD-9-CM) 87 (10.8) 2 (0.9) 85 (14.7) 15 (4.9) 72 (14.5) 11 (4.4) 76 (13.6) 18 (8.5) 69 (11.6)
Coagulopathy (ICD-9-CM) 41 (5.1) 3 (1.3) 38 (6.6) 11 (3.6) 30 (6.0) 12 (4.8) 29 (5.2) 6 (2.8) 35 (5.9)
aOf the 807 patients, 3 (0.4 %) patients had unknown values for respiratory rate; 2 (0.2 %) for pulse, systolic blood pressure, O2 saturation, and temperature; 516 (63.9 %) for bilirubin (component of liver disease);
1 (0.1 %) for platelets (component of bleed risk); and 1 (0.1 %) for glomerular filtration rate (creatinine clearance estimate)
Hrs hours, ICD-9-CM International Classification of Diseases-Ninth Revision-Clinical Modification, min minutes, SD standard deviation, O2 oxygen
bGastrointestinal bleeding in the preceding 14 days, stroke in the preceding 4 weeks, procedure in the preceding 2 weeks, bleeding disorder or thrombocytopenia (platelet count < 75 × 109/L), or uncontrolled
hypertension (systolic blood pressure > 180 mmHg or diastolic blood pressure > 110 mmHg)
cMedical or social reason for hospital treatment was determined by trained study personnel using all data available in the electronic health record including vital signs, laboratory values, and emergency department,
admission and consult notes
dCirrhosis or bilirubin > 2.5 mg/dL











Our study has limitations that require consideration.
First, this validation study was performed retrospectively
and therefore may be subject to biases, particularly due
to missing data. Nonetheless, our study had similar rates
of missing data than reported in prior prospective deriv-
ation/external validation papers of clinical prediction
rules [5–7]. Second, this was a single-center study limit-
ing its generalizability and sample size. However, base-
line characteristics and mortality rates were consistent
with national estimates [10, 15] and our sample size
(573–807 patients) was large relative to many previously
published external validation studies of PE clinical
prediction rules [5]. Third, we could not assess 30 day
mortality in our entire study cohort due to restrictions
on the availability of SSDI data [14]. Despite this, the
sample size of patients with objectively confirmed PE
available for final analysis was robust. Moreover, we are
unaware of any programmatic changes in evaluation and
treatment of patients with PE at our institution since
February 2014. Consequently, the likelihood of selection
bias resulting from the unavoidable exclusion of patients
after this date is low. Next, the more subjective nature of
certain criteria in Hestia (i.e., medical or social reason
for hospital admission and the need for intravenous pain
Table 3 Prognostic test characteristics for 30 day mortality
IMPACT PESI sPESI Hestia
Low-Risk Mortality 1/165 3/218 1/177 0/160
n/N (%) (0.6 %) (1.4 %) (0.6 %) (0 %)
High-Risk Mortality 32/408 30/355 32/396 33/413
n/N (%) (7.8 %) (8.5 %) (8.1 %) (8.0 %)
Sensitivity 97.0 % 90.9 % 97.0 % 100 %
(95 % CI) (82.5–99.8 %) (74.5–97.6 %) (82.5–99.8 %) (87.0–100 %)
Specificity 30.4 % 39.8 % 32.6 % 29.6 %
(95%CI) (26.6–34.5 %) (35.7–44.1 %) (28.7–36.8 %) (25.8–33.7 %)
PPV 7.8 % 8.5 % 8.1 % 8.0 %
(95 % CI) (5.5–11.0 %) (5.9–12.0 %) (5.7–11.3 %) (5.6–11.1 %)
NPV 99.4 % 98.6 % 99.4 % 100 %
(95 % CI) (96.2–100 %) (95.7–99.6 %) (96.4–100 %) (97.1–100 %)
C-statistic 0.804 0.805 0.731 0.791
(95 % CI) (0.749–0.859) (0.731–0.879) (0.653–0.810) (0.721–0.860)
CI confidence interval, IMPACT In-hospital Mortality for Pulmonary embolism using Claims data, NPV negative predictive value, PESI Pulmonary Embolism Severity
Index, PPV positive predictive value, sPESI simplified Pulmonary Embolism Severity Index
Table 2 Prognostic test characteristics for in-hospital mortality
IMPACT PESI sPESI Hestia
Low-Risk Mortality 1/230 2/309 0/250 0/211
n/N (%) (0.4 %) (0.6 %) (0 %) (0 %)
High-Risk Mortality 20/577 19/498 21/557 21/596
n/N (%) (3.5 %) (3.8 %) (3.8 %) (3.5 %)
Sensitivity 95.2 % 90.5 % 100 % 100 %
(95 % CI) (74.1–99.8 %) (68.2–98.3 %) (80.8–100 %) (80.8–100 %)
Specificity 29.1 % 39.1 % 31.8 % 26.8 %
(95 % CI) (26.0–32.5 %) (35.6–42.6 %) (28.6–35.2 %) (23.8–30.1 %)
PPV 3.5 % 3.8 % 3.8 % 3.5 %
(95 % CI) (2.2–5.4 %) (2.4–6.0 %) (2.4–5.8 %) (2.2–5.4 %)
NPV 99.6 % 99.4 % 100 % 100 %
(95 % CI) (97.2–100 %) (97.4–99.9 %) (98.1–100 %) (97.8–100 %)
C-statistic 0.766 0.792 0.762 0.857
(95 % CI) (0.685–0.848) (0.696–0.889) (0.682–0.842) (0.796–0.918)
CI confidence interval, IMPACT In-hospital Mortality for Pulmonary embolism using Claims data, NPV negative predictive value, PESI Pulmonary Embolism Severity
Index, PPV positive predictive value, sPESI simplified Pulmonary Embolism Severity Index
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medication for >24 h), make retrospective scoring chal-
lenging. This being said, the proportion of patients in
our study classified as higher-risk because of these “sub-
jective” criteria was not inconsistent with the Hestia der-
ivation study [8]. Lastly, the 48 h cut-off used to exclude
patients undergoing thrombolysis and/or embolectomy
is somewhat arbitrary. We excluded patients receiving
thrombolysis and/or embolectomy in less than 48 h be-
cause such patients likely had hemodynamic instability
at presentation and would not be considered low-risk
per guidelines [1, 2]. Of note, numerous studies evalu-
ating the prognostic accuracy of clinical prediction
rules have similarly excluded patients undergoing early
thrombolysis and/or embolectomy [5]. However, when
these procedures are performed later in a hospital stay
(day 3 onwards), they are more likely an indicator of a
therapeutic failure resulting in a poor clinical course
(i.e., respiratory failure or cardiac arrest). In addition,
the need for and timing of thrombolysis and/or em-
bolectomy can easily be detected in a claims database
and a clinical setting, allowing it to be implemented in
our evaluation of IMPACT and clinical prediction
rules. The 48 h cut-off was chosen a priori to approxi-
mate the likely timing used for assessing the similar
Hestia criterion (i.e., the Hestia study required dis-
charge within 24 h of PE diagnosis, likely resulting in
the assessment of the 11 Hestia criteria within 48 h of
initial PE presentation) [8].
Conclusion
IMPACT identified low-risk PE patients with similar ac-
curacy as PESI, sPESI and Hestia. While not designed
for prospective clinical decision-making, IMPACT ap-
pears useful for identification of low-risk PE patient in
retrospective claims-based studies.
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